(0.32%) 5 116.28 points
(0.30%) 38 355 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.25%) $2.02
(0.29%) $2 354.10
(0.44%) $27.66
(4.16%) $960.50
(-0.26%) $0.932
(-0.45%) $10.98
(-0.57%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells...
Stats | |
---|---|
本日の出来高 | 12 347.00 |
平均出来高 | 678 764 |
時価総額 | 8.55M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $-0.510 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.370 |
ATR14 | $0.0150 (1.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Silva Francisco | Buy | 6 600 | Common Stock |
2024-04-08 | Silva Francisco | Buy | 1 232 | Common Stock |
2024-04-08 | Silva Francisco | Buy | 476 | Common Stock |
2024-03-18 | Silva Francisco | Sell | 17 193 | Common Stock |
2024-03-18 | Alstodt Lance | Sell | 17 633 | Common Stock |
INSIDER POWER |
---|
92.50 |
Last 100 transactions |
Buy: 3 137 680 | Sell: 202 619 |
ボリューム 相関
BioRestorative Therapies, 相関
10 最も負の相関 | |
---|---|
PBHC | -0.94 |
SCKT | -0.94 |
VORB | -0.938 |
LEXX | -0.936 |
AEY | -0.935 |
HONE | -0.932 |
TBNK | -0.929 |
PEAR | -0.927 |
WNEB | -0.925 |
GBNY | -0.925 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BioRestorative Therapies, 相関 - 通貨/商品
BioRestorative Therapies, 財務諸表
Annual | 2023 |
収益: | $145 800 |
総利益: | $-19 935.00 (-13.67 %) |
EPS: | $-3.42 |
FY | 2023 |
収益: | $145 800 |
総利益: | $-19 935.00 (-13.67 %) |
EPS: | $-3.42 |
FY | 2022 |
収益: | $119 800 |
総利益: | $-160 866 (-134.28 %) |
EPS: | $-4.98 |
FY | 2021 |
収益: | $46 000.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-37.30 |
Financial Reports:
No articles found.
BioRestorative Therapies,
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。